Access breakthrough clinical trials, expert care, and one-on-one patient support all in one place.
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
This study will examine the effectiveness of Acthar® Gel in adults subjects with FSGS who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage).
This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.
Join 2 million participants for a healthier life
Definitely consider the trials. It's so exciting that pharma is finally putting money into FSGS, and we have to participate to help find a cure! I've already participated in one and it was easy and painless.